Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma.

Fiche publication

Date publication

juin 2021

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HOEFFEL Christine

Tous les auteurs :
Barat M, Aldhaheri R, Dohan A, Fuks D, Kedra A, Hoeffel C, Oudjit A, Coriat R, Barret M, Terris B, Marchese U, Soyer P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34206263

Résumé

: To report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and pancreatic ductal adenocarcinoma (PDAC). : Thirty-four patients (24 men, 12 women; mean age, 63.3 ± 10.2 [SD] years) with CT and histopathologically proven PPM were analyzed by two independent readers and compared to 34 patients with PDAC. Diagnosis performances of each variable for the diagnosis of PPM against PDAC were calculated. Univariable and multivariable analyses were performed. A nomogram was developed to diagnose PPM against PDAC. : PPM mostly presented as single (34/34; 100%), enhancing (34/34; 100%), solid (27/34; 79%) pancreatic lesion without visible associated lymph nodes (24/34; 71%) and no Wirsung duct enlargement (29/34; 85%). At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47-29.93; = 0.014), maximal enhancement during arterial phase (OR, 6.15; 95% CI: 1.13-33.51; = 0.036), no vessel involvement (OR, 7.19; 95% CI: 1.512-34.14) and no Wirsung duct dilatation (OR, 10.63; 95% CI: 2.27-49.91) were independently associated with PPM. The nomogram yielded an AUC of 0.92 (95% CI: 0.85-0.98) for the diagnosis of PPM vs. PDAC. : CT findings may help discriminate between PPM and PDAC.